MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ALMR had $34,584K increase in cash & cash equivalents over the period. -$20,947K in free cash flow.

Cash Flow Overview

Change in Cash
$34,584K
Free Cash flow
-$20,947K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of conver...
    • Loss on remeasurement of convert...
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts receivable
    • Payment of deferred offering cos...
    • Others

Cash Flow
2026-03-31
Net loss
-21,325
Depreciation and amortization expense
1,167
Stock-based compensation
1,467
Loss on remeasurement of convertible notes
8,594
Convertible note issuance costs included in net income
361
Unrealized foreign exchange loss (gain)
-165
Non-cash operating lease costs
461
Amortization of debt issuance costs
67
Change in fair value of warrant liabilities
84
Accounts receivable
6,854
Inventory
1,265
Prepaid expenses and other current assets
1,960
Other noncurrent assets
327
Accounts payable
1,339
Operating lease liabilities
-1,087
Accrued expenses and other liabilities
-1,234
Net cash used in operating activities
-20,347
Purchases of property and equipment
600
Capitalized software development costs
178
Net cash (used in) provided by investing activities
-778
Proceeds from issuance of convertible notes
56,500
Payment of third-party debt issuance costs
324
Proceeds from issuance of common stock upon exercise of stock options
1,803
Payment of deferred offering costs
2,218
Net cash provided by financing activities
55,761
Effect of exchange rate changes on cash and cash equivalents, and restricted cash
-52
Net increase in cash, cash equivalents and restricted cash
34,584
Cash, cash equivalents and restricted cash at beginning of period
34,909
Cash, cash equivalents and restricted cash at end of period
69,493
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofconvertible notes$56,500K Proceeds from issuance ofcommon stock upon...$1,803K Net cash provided byfinancing activities$55,761K Canceled cashflow$2,542K Net increase incash, cash...$34,584K Canceled cashflow$21,177K Payment of deferredoffering costs$2,218K Payment of third-partydebt issuance costs$324K Loss onremeasurement of convertible...$8,594K Stock-based compensation$1,467K Accounts payable$1,339K Depreciation andamortization expense$1,167K Non-cash operating leasecosts$461K Convertible note issuancecosts included in net...$361K Unrealized foreignexchange loss (gain)-$165K Change in fair value ofwarrant liabilities$84K Amortization of debt issuancecosts$67K Net cash used inoperating activities-$20,347K Net cash (used in)provided by investing...-$778K Effect of exchange ratechanges on cash and cash...-$52K Canceled cashflow$13,705K Net loss-$21,325K Purchases of property andequipment$600K Capitalized softwaredevelopment costs$178K Accounts receivable$6,854K Prepaid expenses andother current assets$1,960K Inventory$1,265K Accrued expenses andother liabilities-$1,234K Operating leaseliabilities-$1,087K Other noncurrentassets$327K

Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences, Inc. (ALMR)